Medicare AdvantagePrior AuthMedium impact
Secuado® (asenapine) Transdermal System (Revised)
Humana·Psychiatry·Medicare Advantage
Effective date
Jan 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Secuado (asenapine) transdermal patches used to treat schizophrenia. Members must have tried and failed at least 2 other antipsychotic medications before approval.
Action Required
By January 1, 2025: Billing team and providers must obtain prior authorization before prescribing Secuado transdermal patches for Humana Medicare Advantage patients with schizophrenia. Verify patient has documentation showing prior therapy, intolerance, or contraindication to at least 2 of these medications: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or lurasidone. Submit prior auth requests through www.humana.com/PAL. Claims will be denied without proper authorization.